IMMUNOTARGETS AND THERAPY : Impact Factor & More
eISSN: 2253-1556pISSN: 2253-1556
Open AccessShare this on:
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on IMMUNOTARGETS AND THERAPY
IMMUNOTARGETS AND THERAPY Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | DOVE MEDICAL PRESS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2390 |
| Publication Time | 16 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2012 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in IMMUNOTARGETS AND THERAPY ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in IMMUNOTARGETS AND THERAPY
Prognostic and Predictive Value of Peripheral CD8/PD-1/TCF-1 Positive T Cells in Non-Small Cell Lung Carcinoma Patients
- 3 Aug 2026
- ImmunoTargets and Therapy
Increased Expression of HLA-DR and CD69 on Peripheral CD4+ T Cells Predicts Better Clinical Outcomes in Cutaneous Melanoma
- 22 Jul 2026
- ImmunoTargets and Therapy
Near Infrared Photoimmunotherapy for Lung Cancer: Recent Development and Perspective
- 17 Jul 2026
- ImmunoTargets and Therapy
Anlotinib Combined with Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 9 Hydrochloride Suppresses Colorectal Cancer Progression by Inducing Neovascularization and Reprogramming the Tumor Immune Microenvironment in MSS Murine Model
- 30 Jun 2026
- ImmunoTargets and Therapy
Irinotecan Modulates Immune Checkpoints in Neuroblastoma
- 12 Jun 2026
- ImmunoTargets and Therapy
Myeloid Cell-Derived Thrombospondin-1 Mediates Anti-Metastatic Effects of Histamine Dihydrochloride in B16 Melanoma
- 6 Jun 2026
- ImmunoTargets and Therapy
Prognostic and Predictive Value of Peripheral CD8/PD-1/TCF-1 Positive T Cells in Non-Small Cell Lung Carcinoma Patients
- 3 Aug 2026
- ImmunoTargets and Therapy
Increased Expression of HLA-DR and CD69 on Peripheral CD4+ T Cells Predicts Better Clinical Outcomes in Cutaneous Melanoma
- 22 Jul 2026
- ImmunoTargets and Therapy
Near Infrared Photoimmunotherapy for Lung Cancer: Recent Development and Perspective
- 17 Jul 2026
- ImmunoTargets and Therapy
Anlotinib Combined with Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 9 Hydrochloride Suppresses Colorectal Cancer Progression by Inducing Neovascularization and Reprogramming the Tumor Immune Microenvironment in MSS Murine Model
- 30 Jun 2026
- ImmunoTargets and Therapy
Irinotecan Modulates Immune Checkpoints in Neuroblastoma
- 12 Jun 2026
- ImmunoTargets and Therapy
Myeloid Cell-Derived Thrombospondin-1 Mediates Anti-Metastatic Effects of Histamine Dihydrochloride in B16 Melanoma
- 6 Jun 2026
- ImmunoTargets and Therapy
FAQs on IMMUNOTARGETS AND THERAPY
How long has IMMUNOTARGETS AND THERAPY been actively publishing? 
What is the publishing frequency of IMMUNOTARGETS AND THERAPY?
How many articles did IMMUNOTARGETS AND THERAPY publish last year?
What is the eISSN & pISSN for IMMUNOTARGETS AND THERAPY?
Who is the publisher of IMMUNOTARGETS AND THERAPY?
